Clinical Significance of PLA2G2A Expression in Gastric Cancer Patients who Receive Gastrectomy and Adjuvant S-1

Anticancer Res. 2021 Jul;41(7):3583-3588. doi: 10.21873/anticanres.15146.

Abstract

Background/aim: This study aimed to evaluate the prognostic significance of PLA2G2A expression in patients with locally advanced gastric cancer (GC).

Patients and methods: PLA2G2A expression levels in cancerous tissue specimens and adjacent normal mucosa obtained from 134 patients with stage II/III GC who received adjuvant chemotherapy with S-1 after curative resection were measured using real-time quantitative polymerase chain reaction. Subsequently, the associations of PLA2G2A expression with clinicopathological features and survival were evaluated.

Results: No association was observed between clinicopathological features and PLA2G2A expression levels. Overall survival was significantly longer in patients with high PLA2G2A expression levels (p=0.022). Multivariate analysis revealed that PLA2G2A expression was a significant, independent prognostic factor (hazard ratio=0.136; 95% confidence interval=0.0185-0.992; p=0.049).

Conclusion: PLA2G2A mRNA expression may serve as a useful prognostic marker in patients with locally advanced GC who receive curative surgery and adjuvant chemotherapy with S-1.

Keywords: Gastric cancer; PLA2G2A; S-1; prognostic factor.

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use
  • Chemotherapy, Adjuvant / methods
  • Drug Combinations
  • Female
  • Gastrectomy / methods
  • Gastric Mucosa / drug effects
  • Gastric Mucosa / metabolism
  • Gastric Mucosa / pathology
  • Group II Phospholipases A2 / metabolism*
  • Humans
  • Male
  • Neoplasm Staging / methods
  • Oxonic Acid / therapeutic use*
  • Prognosis
  • RNA, Messenger / metabolism
  • Stomach / drug effects
  • Stomach / pathology
  • Stomach / surgery
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / metabolism*
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / surgery
  • Tegafur / therapeutic use*

Substances

  • Antineoplastic Agents
  • Drug Combinations
  • RNA, Messenger
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
  • Group II Phospholipases A2
  • PLA2G2A protein, human